The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.
England's NHS delays hep-C coverage due to pricing; Google reports 21% revenue growth; U.S. and U.K. announce partnership for antibiotic development
The FDA approves generic versions of AstraZeneca's Crestor; Biogen CEO steps down; drugmakers race to develop smart inhalers
EpiPen price hikes led to syringe use; states with medical marijuana laws have drops in drug spending; Pfizer and Merck KGaA start ovarian cancer trial
Gilead CEO talks drug pricing; multiple-sclerosis drugmakers study the overall cost of care; Biden launches national cancer database
Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug
WHO finds poor countries are paying too much for HCV drugs; Gilead faces a lawsuit over an HIV drug; BioMarin to stop developing Duchenne treatment
Valeant has not delivered promised price breaks on heart drugs; AstraZeneca drug receives orphan status; Allergan promotes Meury and Stewart
Rising healthcare costs, coupled with high-profile stories of price gouging at some small pharmaceutical companies, have left consumers feeling ripped off
Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.
Pearson expected to say price hikes were too aggressive; Collegium's painkiller receives full FDA approval; most hospitals stop advertising infant formula
When pharmaceutical companies are needed, we're Jonas Salks; when we ask to be paid, we're Martin Shkrelis.
Government identifies barriers to eliminating hepatitis C; Pearson agrees to congressional deposition; CMS reportedly plans to revoke Theranos license
California bill would require price disclosures; AbbVie's and Genentech's blood-cancer drug is approved; FDA expands metformin use
The drugmaker instead suggested using an economic model it developed.
GSK won't patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.
Pearson to be replaced at Valeant; Pfizer's Xeljanz meets Phase III goals; Harvard partners with Merck on leukemia drug development
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
Exactly how does the erosion of public trust in the goodwill of the pharma industry impact the work being done to raise awareness and also market medicines? It's hard to tell, so far.
We need to consider that not every expenditure is beneficial to patients: perhaps that Super Bowl commercial or that sales meeting in Maui may not be in their best interest.
Providing financial assistance to patients has become a common refrain in drugmakers' defense of high-priced drugs.
Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar
A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."
Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet
We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.
The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.
Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.
Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales
Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business
- 5 Ways to Improve the Customer Experience for Oncologists
- Healthline's traffic rises, putting it closer to WebMD and Everyday Health
- Five things for pharma marketers to know: Wednesday, August 17, 2016
- Five things for pharma marketers to know: Monday, August 22, 2016
- Five things for pharma marketers to know: Thursday, August 18, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- What do physicians think about biosimilars?
- Boehringer Ingelheim launches gamified support program
- The Science and Psychology behind Patient Engagement